Clinical, Laboratory, Molecular, and Reproductive Aspects of Combined Deficiency of Factors V and VIII

Abstract

Congenital combined deficiency of factor V (FV) and factor VIII (FVIII; F5F8D, OMIM 227300) is a rare hereditary coagulopathy and accounts for approximately 3% of cases of rare coagulation disorders. The prevalence of this disease in the general population is estimated to be 1:1,000,000 and is significantly higher in regions where consanguineous marriages are permitted, such as the Mideast and South Asia. The disease has an autosomal recessive mode of inheritance and therefore occurs with an equal incidence among males and females. Heterozygous mutation carriers usually do not have clinical manifestations. The molecular basis of this disease differs from that of stand-alone congenital deficiencies of FVIII and FV. F5F8D is caused by mutations in either LMAN1 or MCFD2, which encode components of a cargo receptor complex for endoplasmic reticulum to Golgi transport of FV and FVIII, leading to defects in an intracellular transport pathway shared by these two coagulation factors. Congenital combined deficiency of FV and FVIII is characterized by decreased activities of both FV and FVIII in plasma, usually to 5 to 30% of normal. Clinical manifestations in most cases are represented by mild or moderate hemorrhagic syndrome. The simultaneous decreases of two coagulation factors present complications in the diagnosis and management of the disease. In female patients, the disease requires a special approach for family planning, pregnancy management, and parturition. This review summarizes recent progress in clinical, laboratory, and molecular understanding of this disorder.

Keywords

bleeding disorder - combined deficiency of FV and FVIII - F5F8D - FV - FVIII - LMAN1

Publication History

Article published online:
29 August 2024

• References

• 1 Oeri J, Matter M, Isenschmid H, Hauser F, Koller F. Angeborener mangel an faktor V (parahaemophilie) verbunden mit echter haemophilie A bein zwei brudern. Mod Probl Paediatr 1954; 1: 575-588
• 2 Seligsohn U, Zivelin A, Zwang E. Combined factor V and factor VIII deficiency among non-Ashkenazi Jews. N Engl J Med 1982; 307 (19) 1191-1195
• 3 Kaufman RJ, Fay PJ, Popolo L, Ortel TL. Factor V and factor VIII. In: Marder VJ, Aird WC, Bennet JS, Schulman S, White GC. eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Philadelphia, PA:: Lippincott William & Wilkins;; 2013: 179-196
• 4 Vos HL. Inherited defects of coagulation factor V: the thrombotic side. J Thromb Haemost 2006; 4 (01) 35-40
• 5 Childers KC, Peters SC, Spiegel Jr PC. Structural insights into blood coagulation factor VIII: procoagulant complexes, membrane binding, and antibody inhibition. J Thromb Haemost 2022; 20 (09) 1957-1970
• 6 Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71 (03) 539-555
• 7 Ayombil F, Abdalla S, Tracy PB, Bouchard BA. Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool. J Thromb Haemost 2013; 11 (08) 1532-1539
• 8 Bouchard BA, Abdalla S, Tracy PB. The factor V light chain mediates the binding and endocytosis of plasma-derived factor V by megakaryocytes. J Thromb Haemost 2013; 11 (12) 2181-2183
• 9 Gould WR, Simioni P, Silveira JR, Tormene D, Kalafatis M, Tracy PB. Megakaryocytes endocytose and subsequently modify human factor V in vivo to form the entire pool of a unique platelet-derived cofactor. J Thromb Haemost 2005; 3 (03) 450-456
• 10 Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood 2014; 123 (24) 3697-3705
• 11 Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 2014; 123 (24) 3706-3713
• 12 Nichols WC, Seligsohn U, Zivelin A. et al. Linkage of combined factors V and VIII deficiency to chromosome 18q by homozygosity mapping. J Clin Invest 1997; 99 (04) 596-601
• 13 Nichols WC, Seligsohn U, Zivelin A. et al. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998; 93 (01) 61-70
• 14 Zhang B, Cunningham MA, Nichols WC. et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet 2003; 34 (02) 220-225
• 15 Zhang B, McGee B, Yamaoka JS. et al. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood 2006; 107 (05) 1903-1907
• 16 Spreafico M, Peyvandi F. Combined factor V and factor VIII deficiency. Semin Thromb Hemost 2009; 35 (04) 390-399
• 17 Zhang B. Recent developments in the understanding of the combined deficiency of FV and FVIII. Br J Haematol 2009; 145 (01) 15-23
• 18 Zhang B, Ginsburg D. Familial multiple coagulation factor deficiencies: new biologic insight from rare genetic bleeding disorders. J Thromb Haemost 2004; 2 (09) 1564-1572
• 19 Zheng C, Zhang B. Combined deficiency of coagulation factors V and VIII: an update. Semin Thromb Hemost 2013; 39 (06) 613-620
• 20 Nufer O, Kappeler F, Guldbrandsen S, Hauri HP. ER export of ERGIC-53 is controlled by cooperation of targeting determinants in all three of its domains. J Cell Sci 2003; 116 (Pt 21): 4429-4440
• 21 Watanabe S, Kise Y, Yonezawa K. et al. Structure of full-length ERGIC-53 in complex with MCFD2 for cargo transport. Nat Commun 2024; 15 (01) 2404
• 22 Zhang B, Kaufman RJ, Ginsburg D. LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem 2005; 280 (27) 25881-25886
• 23 Zheng C, Page RC, Das V. et al. Structural characterization of carbohydrate binding by LMAN1 protein provides new insight into the endoplasmic reticulum export of factors V (FV) and VIII (FVIII). J Biol Chem 2013; 288 (28) 20499-20509
• 24 Nishio M, Kamiya Y, Mizushima T. et al. Structural basis for the cooperative interplay between the two causative gene products of combined factor V and factor VIII deficiency. Proc Natl Acad Sci U S A 2010; 107 (09) 4034-4039
• 25 Wigren E, Bourhis JM, Kursula I, Guy JE, Lindqvist Y. Crystal structure of the LMAN1-CRD/MCFD2 transport receptor complex provides insight into combined deficiency of factor V and factor VIII. FEBS Lett 2010; 584 (05) 878-882
• 26 Satoh T, Nishio M, Suzuki K. et al. Crystallographic snapshots of the EF-hand protein MCFD2 complexed with the intracellular lectin ERGIC-53 involved in glycoprotein transport. Acta Crystallogr F Struct Biol Commun 2020; 76 (Pt 5): 216-221
• 27 Satoh T, Suzuki K, Yamaguchi T, Kato K. Structural basis for disparate sugar-binding specificities in the homologous cargo receptors ERGIC-53 and VIP36. PLoS One 2014; 9 (02) e87963
• 28 Zhang Y, Liu Z, Zhang B. Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII. Blood Adv 2023; 7 (07) 1286-1296
• 29 Cunningham MA, Pipe SW, Zhang B, Hauri HP, Ginsburg D, Kaufman RJ. LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost 2003; 1 (11) 2360-2367
• 30 Zhang Y, Srivastava V, Zhang B. Mammalian cargo receptors for endoplasmic reticulum-to-Golgi transport: mechanisms and interactions. Biochem Soc Trans 2023; 51 (03) 971-981
• 31 Nie C, Wang H, Wang R, Ginsburg D, Chen XW. Dimeric sorting code for concentrative cargo selection by the COPII coat. Proc Natl Acad Sci U S A 2018; 115 (14) E3155-E3162
• 32 Neve EP, Lahtinen U, Pettersson RF. Oligomerization and interacellular localization of the glycoprotein receptor ERGIC-53 is independent of disulfide bonds. J Mol Biol 2005; 354 (03) 556-568
• 33 Appenzeller-Herzog C, Roche AC, Nufer O, Hauri HP. pH-induced conversion of the transport lectin ERGIC-53 triggers glycoprotein release. J Biol Chem 2004; 279 (13) 12943-12950
• 34 Jackson LP, Lewis M, Kent HM. et al. Molecular basis for recognition of dilysine trafficking motifs by COPI. Dev Cell 2012; 23 (06) 1255-1262
• 35 Ma W, Goldberg J. Rules for the recognition of dilysine retrieval motifs by coatomer. EMBO J 2013; 32 (07) 926-937
• 36 Karampini E, Bierings R, Voorberg J. Orchestration of primary hemostasis by platelet and endothelial lysosome-related organelles. Arterioscler Thromb Vasc Biol 2020; 40 (06) 1441-1453
• 37 Naß J, Terglane J, Gerke V. Weibel Palade bodies: unique secretory organelles of endothelial cells that control blood vessel homeostasis. Front Cell Dev Biol 2021; 9: 813995
• 38 Khoriaty R, Vasievich MP, Ginsburg D. The COPII pathway and hematologic disease. Blood 2012; 120 (01) 31-38
• 39 Zhang Y, Zhu M, Zheng C, Wei W, Emmer BT, Zhang B. LMAN1-MCFD2 complex is a cargo receptor for the ER-Golgi transport of α1-antitrypsin. Biochem J 2022; 479 (07) 839-855
• 40 Nyfeler B, Reiterer V, Wendeler MW. et al. Identification of ERGIC-53 as an intracellular transport receptor of alpha1-antitrypsin. J Cell Biol 2008; 180 (04) 705-712
• 41 Zhang B, Zheng C, Zhu M. et al. Mice deficient in LMAN1 exhibit FV and FVIII deficiencies and liver accumulation of α1-antitrypsin. Blood 2011; 118 (12) 3384-3391
• 42 Zhu M, Zheng C, Wei W, Everett L, Ginsburg D, Zhang B. Analysis of MCFD2- and LMAN1-deficient mice demonstrates distinct functions in vivo. Blood Adv 2018; 2 (09) 1014-1021
• 43 Biss TT, Blanchette VS, Clark DS. et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010; 8 (05) 950-956
• 44 Rodeghiero F, Tosetto A, Abshire T. et al; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8 (09) 2063-2065
• 45 Peyvandi F, Palla R, Menegatti M. et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (04) 615-621
• 46 Zhu M, Das V, Zheng C, Majumdar S, Zhang B. A synonymous mutation in LMAN1 creates an ectopic splice donor site and causes combined deficiency of FV and FVIII. J Thromb Haemost 2012; 10 (11) 2407-2409
• 47 Yang W, Mu H, Zhou F, Wang J, Bi H, Zhou Z. Successful hip arthroplasty in a patient with combined deficiency of factor V and factor FVIII. Haemophilia 2023; 30 (02) 558-560
• 48 Mansouritorgabeh H, Rezaieyazdi Z, Pourfathollah AA, Rezai J, Esamaili H. Haemorrhagic symptoms in patients with combined factors V and VIII deficiency in north-eastern Iran. Haemophilia 2004; 10 (03) 271-275
• 49 Peyvandi F, Tuddenham EG, Akhtari AM, Lak M, Mannucci PM. Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. Br J Haematol 1998; 100 (04) 773-776
• 50 Shetty S, Madkaikar M, Nair S. et al. Combined factor V and VIII deficiency in Indian population. Haemophilia 2000; 6 (05) 504-507
• 51 Viswabandya A, Baidya S, Nair SC. et al. Clinical manifestations of combined factor V and VIII deficiency: a series of 37 cases from a single center in India. Am J Hematol 2010; 85 (07) 538-539
• 52 Shao Y, Wu W, Xu G, Wang X, Ding Q. Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII. Blood 2019; 134 (20) 1745-1754
• 53 Spiliopoulos D, Kadir RA. Congenital factor V and VIII deficiency in women: a systematic review of literature and report of two new cases. Blood Coagul Fibrinolysis 2016; 27 (03) 237-241
• 54 Bolton-Maggs PH, Perry DJ, Chalmers EA. et al. The rare coagulation disorders–review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10 (05) 593-628
• 55 Spreafico M, Peyvandi F. Combined FV and FVIII deficiency. Haemophilia 2008; 14 (06) 1201-1208
• 56 Zhang B, Spreafico M, Zheng C. et al. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood 2008; 111 (12) 5592-5600
• 57 Neerman-Arbez M, Johnson KM, Morris MA. et al. Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. Blood 1999; 93 (07) 2253-2260
• 58 Patel AJ, Liu HH, Lager RA, Malkovska V, Zhang B. Successful percutaneous coronary intervention in a patient with combined deficiency of FV and FVIII due to novel compound heterozygous mutations in LMAN1. Haemophilia 2013; 19 (04) 607-610
• 59 Nyfeler B, Kamiya Y, Boehlen F. et al. Deletion of 3 residues from the C-terminus of MCFD2 affects binding to ERGIC-53 and causes combined factor V and factor VIII deficiency. Blood 2008; 111 (03) 1299-1301
• 60 Yamada T, Fujimori Y, Suzuki A. et al. A novel missense mutation causing abnormal LMAN1 in a Japanese patient with combined deficiency of factor V and factor VIII. Am J Hematol 2009; 84 (11) 738-742
• 61 Zheng C, Liu HH, Yuan S, Zhou J, Zhang B. Molecular basis of LMAN1 in coordinating LMAN1-MCFD2 cargo receptor formation and ER-to-Golgi transport of FV/FVIII. Blood 2010; 116 (25) 5698-5706
• 62 Zheng C, Liu HH, Zhou J, Zhang B. EF-hand domains of MCFD2 mediate interactions with both LMAN1 and coagulation factor V or VIII. Blood 2010; 115 (05) 1081-1087
• 63 Mumford AD, Ackroyd S, Alikhan R. et al; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (03) 304-326
• 64 Garcia VV, Silva IA, Borrasca AL. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII). Thromb Haemost 1982; 48 (01) 91-93
• 65 Guglielmone H, Minoldo S, Jarchum G. Response to the DDAVP test in a patient with combined deficiency of factor V and factor VIII. Haemophilia 2009; 15 (03) 838-839
• 66 Sirachainan N, Zhang B, Chuansumrit A, Pipe S, Sasanakul W, Ginsburg D. Combined factor V and factor VIII deficiency in a Thai patient: a case report of genotype and phenotype characteristics. Haemophilia 2005; 11 (03) 280-284
• 67 Dahlbäck B. Human coagluation factor V purification and thrombin-catalyzed activation. J Clin Invest 1980; 66 (03) 583-591
• 68 Rosenberg JS, Beeler DL, Rosenberg RD. Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin. J Biol Chem 1975; 250 (05) 1607-1617
• 69 Bulato C, Novembrino C, Anzoletti MB. et al. “In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate. Haemophilia 2018; 24 (04) 648-656
• 70 Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost 2009; 35 (04) 382-389
• 71 Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia 2008; 14 (06) 1164-1169
• 72 Yakovleva EV, Efimov IV, Kostin AI. et al. Diagnosis and choice of haemostatic therapy during surgery in patients with combined coagulation factor V and VIII deficiency. Russ J Hematol Transfusiol 2021; 66 (01) 79-87
• 73 Buckner TW, Nielsen BI, Key NS, Ma A. Factor VIII inhibitory antibody in a patient with combined factor V/factor VIII deficiency. Haemophilia 2015; 21 (01) e77-e80
• 74 Yakovleva EV, Gorgidze L, Konyashina NI. Use of cryoprecipitate in treatment of inherited factor V deficiency and inherited combined factor V and factor VIII deficiency. Haemopchilia 2020; 26 (S2): 149
• 75 Di Marzio I, Iuliani O, Malizia R. et al. Successful use of recombinant FVIIa in combined factor V and FVIII deficiency with surgical bleeding resistant to substitutive treatment. A case report. Haemophilia 2011; 17 (01) 160-161
• 76 Lechner D, Eichinger S, Wanivenhaus A, Kyrle PA. Peri-interventional control of haemostasis in a patient with combined coagulation factor V- and factor VIII-deficiency and anaphylaxis to fresh frozen plasma - a rare indication for recombinant factor VIIa. Haemophilia 2010; 16 (04) 704-705
• 77 Bouchard BA, Chapin J, Brummel-Ziedins KE, Durda P, Key NS, Tracy PB. Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency. Blood 2015; 125 (23) 3647-3650
• 78 Yakovleva EV, Konyashina NI, Gorgidze LA. et al. Congenital factor V deficiency: case reports. Russ J Hematol Transfusiol 2019; 64 (04) 489-503
• 79 Duckers C, Simioni P, Spiezia L. et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112 (09) 3615-3623
• 80 Santamaria S, Reglińska-Matveyev N, Gierula M. et al. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. J Biol Chem 2017; 292 (22) 9335-9344
• 81 Dahlbäck B. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S. J Thromb Haemost 2017; 15 (07) 1241-1250
• 82 Huq FY, Kulkarni A, Agbim EC, Riddell A, Tuddenham E, Kadir RA. Changes in the levels of factor VIII and von Willebrand factor in the puerperium. Haemophilia 2012; 18 (02) 241-245
• 83 Janbain M, Kouides P. Managing pregnant women with Hemophilia and von Willebrand disease: how do we provide optimum care and prevent complications?. Int J Womens Health 2022; 14: 1307-1313
• 84 Oukkache B, El Graoui O, Zafad S. Combined factor V and VIII deficiency and pregnancy. Int J Hematol 2012; 96 (06) 786-788
• 85 Fogarty H, Doyle MM, Campbell R. et al. Management of combined factor V and factor VIII deficiency in pregnancy. J Obstet Gynaecol 2019; 39 (02) 271-272
• 86 Chi C, Shiltagh N, Kingman CE, Economides DL, Lee CA, Kadir RA. Identification and management of women with inherited bleeding disorders: a survey of obstetricians and gynaecologists in the United Kingdom. Haemophilia 2006; 12 (04) 405-412
• 87 Huq FY, Kadir RA. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia 2011; 17 (Suppl. 01) 20-30
• 88 Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia 2009; 15 (05) 990-1005
• 89 Kadir RA, Davies J, Winikoff R. et al. Pregnancy complications and obstetric care in women with inherited bleeding disorders. Haemophilia 2013; 19 (Suppl. 04) 1-10
• 90 Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol 2004; 112 (02) 154-157
• 91 Lee CA, Chi C, Pavord SR. et al; UK Haemophilia Centre Doctors' Organization. The obstetric and gynaecological management of women with inherited bleeding disorders–review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006; 12 (04) 301-336
• 92 Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993; 70 (02) 238-240
• 93 Orgul G, Aktoz F, Beksac MS. Impact of rare bleeding disorders during pregnancy on maternal and fetal outcomes: review of 29 pregnancies at a single center. Rev Bras Ginecol Obstet 2017; 39 (01) 4-8
• 94 Alyafee Y, Al Tuwaijri A, Umair M. et al. Non-invasive prenatal testing for autosomal recessive disorders: a new promising approach. Front Genet 2022; 13: 1047474
• 95 Horn R. NIPT and the concerns regarding ‘routinisation’. Eur J Hum Genet 2022; 30 (06) 637-638
• 96 Andrew M, Paes B, Milner R. et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70 (01) 165-172
• 97 Mitsiakos G, Katsaras GN, Pouliakis A. et al. Neonatal haemostatic parameters in correlation to gestational age and birth weight. Int J Lab Hematol 2022; 44 (05) 952-958